Get the Stockscreener App
2.31
6.45%
0.14
Annexon Inc stock is traded at $2.31, with a volume of 1.95M.
It is up +6.45% in the last 24 hours and down -2.53% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.17
Open:
$2.2
24h Volume:
1.95M
Relative Volume:
1.34
Market Cap:
$253.44M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.3051
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-5.33%
1M Performance:
-2.53%
6M Performance:
-17.79%
1Y Performance:
-60.17%
1-Day Range:
$2.19
$2.355
1-Week Range:
$2.07
$2.567
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.31 | 258.23M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Inc. Sees Relief Buying After Extended Drop2025 Macro Impact & Growth Focused Stock Reports - newsyoung.net
How to forecast Annexon Inc. trends using time series2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - Newser
What moving averages say about Annexon Inc.July 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
Developing predictive dashboards with Annexon Inc. dataMarket Trend Report & AI Enhanced Trading Signals - Newser
Is Annexon Inc. stock reversal real or fake2025 Risk Factors & Consistent Profit Trading Strategies - Newser
How hedge fund analytics apply to Annexon Inc. stockCEO Change & Weekly Market Pulse Updates - Newser
Will Annexon Inc. see short term momentumQuarterly Market Summary & Risk Managed Investment Strategies - Newser
How to use a screener to detect Annexon Inc. breakoutsQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Strategies to average down on Annexon Inc.2025 Growth vs Value & Daily Volume Surge Trade Alerts - Newser
Using AI based signals to follow Annexon Inc.2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Will breakout in Annexon Inc. lead to full recoveryJuly 2025 Intraday Action & Growth Focused Entry Point Reports - Newser
Can you recover from losses in Annexon Inc.2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - Newser
Can volume confirm reversal in Annexon Inc.Quarterly Trade Summary & Advanced Swing Trade Entry Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Applying Wyckoff theory to Annexon Inc. stockDividend Hike & Expert Approved Momentum Trade Ideas - Newser
Equity Incentive Trends in Biotech: Assessing Annexon's Recent Grant and Its Implications for Talent Retention and Growth - AInvest
Annexon Reports Inducement Grant to New Employee Under Nasdaq Li - GuruFocus
Annexon reports inducement grant to new employee under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
60,000 Share Options at $2.44: Annexon Grants Inducement Award Under Nasdaq Employment Plan - Stock Titan
Will Annexon Inc. stock go up soon2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - Newser
Annexon Reports Q2 2025 Earnings Miss, Spikes Short-Term Gains Amid Volatility - AInvest
What makes Annexon Inc. stock attractive to long term investors2025 Momentum Check & Weekly Sector Rotation Insights - Newser
Annexon Inc's Q2 2025 EPS Beats Estimates, with Robust Cash Position and Strong Pipeline Progress - AInvest
Will Annexon Inc. benefit from macro trendsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Signal strength of Annexon Inc. stock in tech scannersEarnings Growth Report & Risk Controlled Daily Plans - Newser
Will Annexon Inc. rebound enough to break evenPortfolio Update Summary & Free Weekly Watchlist of Top Performers - Newser
Using RSI to spot recovery in Annexon Inc.Market Weekly Review & Daily Volume Surge Signals - Newser
What machine learning models say about Annexon Inc.Weekly Stock Analysis & Free Weekly Watchlist of Top Performers - Newser
Is Annexon Inc. stock risky to hold nowMarket Movers & Risk Managed Trade Strategies - newsyoung.net
How Interest Rate Changes Impact Annexon Inc. Stock PerformanceGold Moves & Growth Focused Stock Pick Reports - Newser
Annexon Misses Q2 Earnings, Drives Short-Term Gains Amid Biotech Sector Resilience - AInvest
HC Wainwright Reaffirms “Buy” Rating for Annexon (NASDAQ:ANNX) - Defense World
Trend analysis for Annexon Inc. this weekJuly 2025 Retail & Technical Pattern Alert System - Newser
Annexon Biosciences Faces Financial Risks Amid Global Trade Challenges - MSN
Price momentum metrics for Annexon Inc. explainedBull Run & Safe Capital Growth Plans - Newser
Why Annexon Inc. stock attracts strong analyst attentionMarket Trend Review & Fast Gain Stock Tips - thegnnews.com
Applying sector rotation models to Annexon Inc.Portfolio Return Report & Low Volatility Stock Recommendations - Newser
Annexon Biosciences Receives Buy Rating and $14 Price Target from Wells Fargo Analyst - AInvest
Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability - TipRanks
Annexon Biosciences Reports Q2 2025 Financial Results - TipRanks
Regression Model Predicts Rangebound Movement in Annexon Inc.2025 Geopolitical Influence & Risk Controlled Stock Alerts - sundaytimes.kr
Annexon's Path to Commercialization: Assessing Clinical Milestones and Financial Viability in a High-Risk, High-Reward Biotech Play - AInvest
Annexon Narrows Loss in Fiscal Q2 - The Globe and Mail
Annexon Biosciences Q2 GAAP EPS of -$0.34 Beats Estimates - AInvest
Annexon Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annexon reports Q2 EPS (34c), consensus (36c) - TipRanks
Annexon's Strategic Momentum in 2025: Near-Term Catalysts and Long-Term Value Creation - AInvest
Annexon Reports Q2 2025 Financial Results and Highlights Portfolio Progress, Anticipated Milestones for Tanruprubart, Vonaprument, and ANX1502 - AInvest
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
How Annexon Inc. stock performs during market volatilityAnalyst Downgrade & Safe Capital Growth Plans - Newser
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,116 |
2,879 |
105,084 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Jul 14 '25 |
Sale |
2.58 |
1,117 |
2,882 |
121,616 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Jul 14 '25 |
Sale |
2.61 |
853 |
2,226 |
130,689 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):